Lilly FDA Approved Jaypirca (pirtobrutinib)
Lilly USA, LLC is pleased to announce that the US Food and Drug Administration (FDA) has approved Jaypirca™ (pirtobrutinib), 50 mg and 100 mg tablets, on January 27, 2023, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For additional information, please see the press release here.
Jaypirca is now available for ordering, and shipping is anticipated to begin on or after the week of February 6, 2023.
If you would like to discuss information associated with this newly approved treatment option in more detail, please feel free to contact Kevin Coyne via email (firstname.lastname@example.org) or call 570-406-1548 to schedule a time.
Members can view full details at: Drug Updates